AU2007317242B2 - Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto - Google Patents
Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto Download PDFInfo
- Publication number
- AU2007317242B2 AU2007317242B2 AU2007317242A AU2007317242A AU2007317242B2 AU 2007317242 B2 AU2007317242 B2 AU 2007317242B2 AU 2007317242 A AU2007317242 A AU 2007317242A AU 2007317242 A AU2007317242 A AU 2007317242A AU 2007317242 B2 AU2007317242 B2 AU 2007317242B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- isobutyl
- dimethoxy
- pyrido
- hexahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86494406P | 2006-11-08 | 2006-11-08 | |
| US60/864,944 | 2006-11-08 | ||
| PCT/US2007/084176 WO2008058261A1 (en) | 2006-11-08 | 2007-11-08 | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007317242A1 AU2007317242A1 (en) | 2008-05-15 |
| AU2007317242B2 true AU2007317242B2 (en) | 2013-08-01 |
Family
ID=39110526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007317242A Active AU2007317242B2 (en) | 2006-11-08 | 2007-11-08 | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8039627B2 (enExample) |
| EP (1) | EP2081929B1 (enExample) |
| JP (1) | JP5290185B2 (enExample) |
| KR (1) | KR101500766B1 (enExample) |
| CN (1) | CN101553487B (enExample) |
| AU (1) | AU2007317242B2 (enExample) |
| BR (1) | BRPI0718247B1 (enExample) |
| CA (1) | CA2668689C (enExample) |
| DK (1) | DK2081929T3 (enExample) |
| EA (1) | EA018378B1 (enExample) |
| ES (1) | ES2402220T3 (enExample) |
| IL (1) | IL198250A0 (enExample) |
| MX (1) | MX2009004910A (enExample) |
| PL (1) | PL2081929T3 (enExample) |
| PT (1) | PT2081929E (enExample) |
| WO (1) | WO2008058261A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007317242B2 (en) | 2006-11-08 | 2013-08-01 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
| EP3345905B1 (en) | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012000308A1 (zh) * | 2010-06-29 | 2012-01-05 | 中国药科大学 | 丁苯那嗪的拆分方法 |
| US8351329B2 (en) * | 2010-09-14 | 2013-01-08 | Cisco Technology, Inc. | Universal load-balancing tunnel encapsulation |
| CN102285984B (zh) * | 2010-11-25 | 2012-10-10 | 江苏威凯尔医药科技有限公司 | (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法 |
| WO2012081031A1 (en) | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| JP6362601B2 (ja) | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP2951178A4 (en) * | 2013-01-31 | 2016-07-06 | Auspex Pharmaceuticals Inc | VMAT2 INHIBITORS OF BENZOQUINOLONE TYPE |
| WO2015048370A1 (en) * | 2013-09-27 | 2015-04-02 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| CA2930744A1 (en) * | 2013-12-03 | 2015-06-11 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| MX2016009817A (es) * | 2014-01-27 | 2017-02-28 | Auspex Pharmaceuticals Inc | Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2. |
| CN106061506A (zh) * | 2014-02-07 | 2016-10-26 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| EA201691582A1 (ru) | 2014-02-07 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Новые фармацевтические препараты |
| PT3105218T (pt) | 2014-02-13 | 2019-12-05 | Incyte Corp | Ciclopropilaminas como inibidores de lsd1 |
| KR20220140647A (ko) * | 2014-05-06 | 2022-10-18 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 |
| MX375718B (es) | 2015-02-06 | 2025-03-06 | Neurocrine Biosciences Inc | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. |
| IL288712B2 (en) | 2015-03-06 | 2024-01-01 | Auspex Pharmaceuticals Inc | Methods for the treatment of abnormal involuntary movement disorders |
| EP3626720A1 (en) | 2015-04-03 | 2020-03-25 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| CN113713108A (zh) * | 2015-06-23 | 2021-11-30 | 纽罗克里生物科学有限公司 | 用于治疗神经学疾病或病症的vmat2抑制剂 |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| MX383906B (es) | 2015-10-09 | 2025-03-14 | Teva Pharmaceuticals Int Gmbh | Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson |
| LT3875459T (lt) * | 2015-10-30 | 2024-02-26 | Neurocrine Biosciences, Inc. | Valbenazino dihidrochlorido druskos ir jų polimorfai |
| CA3009169A1 (en) * | 2015-12-23 | 2017-06-29 | Neurocrine Biosciences, Inc. | Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
| US10479787B2 (en) | 2016-04-22 | 2019-11-19 | Lupin Limited | Process for preparation of tetrabenazine and deutetrabenazine |
| EP3473623B1 (en) * | 2016-06-29 | 2020-07-15 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal forms of nbi-98854, preparation method therefor and use thereof |
| RU2019110048A (ru) | 2016-10-06 | 2020-11-06 | Ассиа Кемикал Индастрис Лтд. | Твердые формы валбеназина |
| JP2020500875A (ja) | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| US10703750B2 (en) | 2017-01-10 | 2020-07-07 | Sandoz Ag | Crystalline valbenazine free base |
| JP7090151B2 (ja) | 2017-01-27 | 2022-06-23 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| US10954235B2 (en) | 2017-02-27 | 2021-03-23 | Sandoz Ag | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| WO2018170214A1 (en) | 2017-03-15 | 2018-09-20 | Zhang Chengzi | Analogs of deutetrabenazine, their preparation and use |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| CN110691596A (zh) * | 2017-04-01 | 2020-01-14 | 阿德普蒂奥制药有限公司 | 药物组合物 |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| JOP20190239A1 (ar) * | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| MA50175B1 (fr) | 2017-09-21 | 2025-05-30 | Neurocrine Biosciences, Inc. | Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés |
| AU2017435893B2 (en) | 2017-10-10 | 2023-06-29 | Neurocrine Biosciences, Inc | Methods for the administration of certain VMAT2 inhibitors |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| WO2019094491A1 (en) * | 2017-11-08 | 2019-05-16 | Yuhua Li | Esters of dihydrotetrabenazine |
| KR102776189B1 (ko) | 2017-11-22 | 2025-03-04 | 아시아 케미컬 인더스트리스 리미티드 | 발베나진의 고상 형태 |
| CA3086611C (en) | 2017-12-26 | 2023-07-25 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof |
| CN110092785A (zh) * | 2018-01-31 | 2019-08-06 | 广东东阳光药业有限公司 | 一种丁苯那嗪的动态拆分方法 |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| WO2019241555A1 (en) * | 2018-06-14 | 2019-12-19 | Neurocrine Biosciences, Inc. | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
| SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| WO2020070236A1 (en) | 2018-10-04 | 2020-04-09 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| CA3065236A1 (en) | 2018-12-27 | 2020-06-27 | Apotex Inc. | Novel crystalline form of valbenazine dibesylate |
| WO2020213014A1 (en) | 2019-04-19 | 2020-10-22 | Mylan Laboratories Limited | An improved process for the preparation of valbenazine and its salts |
| US10689380B1 (en) | 2019-07-30 | 2020-06-23 | Farmhispania S.A. | Crystalline forms of valbenazine ditosylate |
| WO2021027792A1 (zh) * | 2019-08-12 | 2021-02-18 | 山东绿叶制药有限公司 | Vmat2抑制剂及其制备方法和应用 |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| CN114423755A (zh) | 2019-09-13 | 2022-04-29 | 纽罗克里生物科学有限公司 | 用于合成缬苯那嗪的方法 |
| CN110698397A (zh) * | 2019-10-28 | 2020-01-17 | 南京红杉生物科技有限公司 | 丁苯那嗪中间体及其合成方法、应用和合成用中间产物 |
| HRP20250868T1 (hr) | 2021-03-22 | 2025-09-26 | Neurocrine Biosciences, Inc. | Vmat2 inhibitori i postupci za uporabu |
| IL307826A (en) | 2021-04-26 | 2023-12-01 | Neurocrine Biosciences Inc | Processes for the synthesis of valbanazine |
| JP2024524324A (ja) | 2021-06-30 | 2024-07-05 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症のアドオン処置において使用するためのバルベナジン |
| EP4362942A1 (en) | 2021-06-30 | 2024-05-08 | Neurocrine Biosciences, Inc. | Valbenazine for use in the treatment of dyskinesia due to cerebral palsy |
| AU2023232134A1 (en) | 2022-03-07 | 2024-10-03 | Neurocrine Biosciences, Inc. | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
| JP2025531352A (ja) | 2022-09-21 | 2025-09-19 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | ヘキサヒドロ－２ｈ－ピリド［２，１－ａ］イソキノリンｖｍａｔ２阻害剤および使用の方法 |
| TW202521119A (zh) | 2023-08-17 | 2025-06-01 | 美商紐羅克里生物科學有限公司 | 用於投與特定vmat2抑制劑之方法 |
| WO2025038959A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025096823A1 (en) | 2023-11-01 | 2025-05-08 | Neurocrine Biosciences, Inc. | Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine |
| WO2025188830A1 (en) | 2024-03-06 | 2025-09-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025199234A1 (en) | 2024-03-20 | 2025-09-25 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2843591A (en) * | 1958-07-15 | Method for preparing same | ||
| US3209005A (en) * | 1965-09-28 | Hexahydro-llbh-benzo[a] quinolizines and processes therefor | ||
| US2852518A (en) * | 1957-05-23 | 1958-09-16 | Parke Davis & Co | Di-substituted quinoline compounds |
| AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| US6610841B1 (en) | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
| US7045543B2 (en) * | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| CA2623794A1 (en) | 2005-06-29 | 2007-01-11 | The Trustees Of Columbia University In The City Of New York | Use of dtbz for imaging endocrine pancreas and beta cell mass in type 1 diabetes |
| GB0514501D0 (en) | 2005-07-14 | 2005-08-24 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| GB0516168D0 (en) | 2005-08-05 | 2005-09-14 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| US20110257220A1 (en) | 2005-08-06 | 2011-10-20 | Cambridge Laboratories (Ireland) Limited | 3,11 b-cis-Dihydrotetrabenazine for the Treatment of Schizophrenia and Other Psychoses |
| AU2007317242B2 (en) | 2006-11-08 | 2013-08-01 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
-
2007
- 2007-11-08 AU AU2007317242A patent/AU2007317242B2/en active Active
- 2007-11-08 EP EP07864160A patent/EP2081929B1/en active Active
- 2007-11-08 EA EA200970461A patent/EA018378B1/ru unknown
- 2007-11-08 US US11/937,445 patent/US8039627B2/en active Active
- 2007-11-08 CN CN2007800395790A patent/CN101553487B/zh active Active
- 2007-11-08 CA CA2668689A patent/CA2668689C/en active Active
- 2007-11-08 WO PCT/US2007/084176 patent/WO2008058261A1/en not_active Ceased
- 2007-11-08 KR KR1020097011731A patent/KR101500766B1/ko active Active
- 2007-11-08 DK DK07864160.2T patent/DK2081929T3/da active
- 2007-11-08 PL PL07864160T patent/PL2081929T3/pl unknown
- 2007-11-08 ES ES07864160T patent/ES2402220T3/es active Active
- 2007-11-08 JP JP2009536493A patent/JP5290185B2/ja active Active
- 2007-11-08 PT PT78641602T patent/PT2081929E/pt unknown
- 2007-11-08 BR BRPI0718247-3A patent/BRPI0718247B1/pt active IP Right Grant
- 2007-11-08 MX MX2009004910A patent/MX2009004910A/es active IP Right Grant
-
2009
- 2009-04-21 IL IL198250A patent/IL198250A0/en active IP Right Grant
-
2011
- 2011-09-20 US US13/237,709 patent/US8357697B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| ARANDA, G. et al, "Synthesis and biological activity of iodinated and photosensitive derivatives of tetrabenazine", European Journal of Medicinal Chemistry, 1990, Vol. 25, pages 369-374 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2402220T8 (es) | 2021-12-23 |
| KR20090079257A (ko) | 2009-07-21 |
| US8039627B2 (en) | 2011-10-18 |
| CN101553487B (zh) | 2012-06-13 |
| EA018378B1 (ru) | 2013-07-30 |
| WO2008058261A1 (en) | 2008-05-15 |
| EA200970461A1 (ru) | 2009-12-30 |
| US20120077839A1 (en) | 2012-03-29 |
| CA2668689C (en) | 2015-12-29 |
| MX2009004910A (es) | 2009-07-24 |
| IL198250A0 (en) | 2009-12-24 |
| EP2081929A1 (en) | 2009-07-29 |
| ES2402220T3 (es) | 2013-04-29 |
| PT2081929E (pt) | 2013-04-15 |
| JP2010509366A (ja) | 2010-03-25 |
| BRPI0718247B1 (pt) | 2021-09-21 |
| AU2007317242A1 (en) | 2008-05-15 |
| JP5290185B2 (ja) | 2013-09-18 |
| CN101553487A (zh) | 2009-10-07 |
| BRPI0718247A2 (pt) | 2014-01-07 |
| PL2081929T3 (pl) | 2013-06-28 |
| EP2081929B1 (en) | 2013-01-09 |
| US20080167337A1 (en) | 2008-07-10 |
| CA2668689A1 (en) | 2008-05-15 |
| KR101500766B1 (ko) | 2015-03-16 |
| KR101500766B9 (ko) | 2024-09-25 |
| DK2081929T3 (da) | 2013-04-15 |
| US8357697B2 (en) | 2013-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007317242B2 (en) | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto | |
| AU2008317375B2 (en) | Deuterated darunavir | |
| EP2982674B1 (en) | Pyridinylpyrazoloquinoline compound | |
| CA3008653A1 (en) | Bruton's tyrosine kinase inhibitors | |
| SA95160370B1 (ar) | مركبات سبيرو-أزا ثنائية الحلقات Spiro -azabicyclic مفيدة في العلاج | |
| AU743929B2 (en) | Morphinane derivatives and medicinal use thereof | |
| SK20199A3 (en) | Ether muscarinic antagonists | |
| CA3114646C (en) | Quinolino-pyrrolidin-2-one derivatives and application thereof | |
| AU763357B2 (en) | Mevinolin derivatives | |
| JPH07503703A (ja) | （−）−エゼロリン、（−）−ｎ１−ノルエゼロリンおよび（−）−ｎ１−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩：特異的アセチルコリンエステラーゼ阻害薬としての使用 | |
| EP4491228A2 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| JP7702384B2 (ja) | Ｖｍａｔ２阻害剤、及びその調製方法、及びその使用 | |
| EP0693070B1 (en) | PYRIDO[2,3-b](1,4)BENZODIAZEPINONES AS M2 RECEPTOR LIGAND FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
| EP3867244B1 (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | |
| CN118302418B (zh) | 一种芳杂环类化合物及其应用 | |
| EP3937917B1 (en) | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | |
| EP4159736A1 (en) | Novel tricyclic aromatic heterocyclic compound and preparation method therefor, pharmaceutical composition and use thereof | |
| EP4006029A1 (en) | Macrocyclic derivatives as factor xia inhibitors | |
| IL317345A (en) | Tricyclic substances and pharmaceutical preparations containing them | |
| CS411291A3 (en) | Pilocarpine derivatives, process of their preparation and a pharmaceutical comprising thereof | |
| HK40033047B (en) | Imidazopyridine derivatives and the use thereof as medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |